All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Takeda Pharmaceutical Co. Ltd. is leading a $125 million investment in Maverick Therapeutics Inc., a company founded with initial financing from MPM Capital that is working to improve the utility of T-cell redirection therapy for the treatment of cancer. The financing, encompassing both equity investment and R&D funding, provides Takeda an exclusive option to buy the company after five years for an undisclosed amount.